Previous 10 | Next 10 |
Image source: The Motley Fool. Global Blood Therapeutics (NASDAQ: GBT) Q1 2022 Earnings Call May 04, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Global Blood Therapeutics (GBT) Q1 2022 Earnings Call Transcript ...
Global Blood Therapeutics, Inc. (GBT) Q1 2022 Earnings Conference Call May 04, 2022 4:30 PM ET Company Participants Steven Immergut – Senior Vice Preside, Head-Corporate Communications and Investor Relations Ted Love – President and Chief Executive Officer Jeff Farrow – C...
Global Blood Therapeutics press release (NASDAQ:GBT): Q1 GAAP EPS of -$1.26 beats by $0.06. Revenue of $55.16M (+41.3% Y/Y) misses by $0.97M. For further details see: Global Blood Therapeutics GAAP EPS of -$1.26 beats by $0.06, revenue of $55.16M misses by $0.97M
Achieved Oxbryta ® (voxelotor) net revenues of $55.2 million in the first quarter 2022, a 41% increase year over year Strong new prescription growth driven by the recent launch for children ages 4 to less than 12 years and improving trends for patients ages 12 y...
Global Blood Therapeutics (NASDAQ:GBT) is scheduled to announce Q1 earnings results on Wednesday, May 4th, after market close. The consensus EPS Estimate is -$1.36 and the consensus Revenue Estimate is $56.13M (+43.8% Y/Y). Over the last 1 year, GBT has beaten EPS estimates 25% of the time an...
SOUTH SAN FRANCISCO, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT), a biopharmaceutical company dedicated to meeting the needs of underserved patient communities starting with sickle cell disease (SCD), today released its inaugural environm...
SOUTH SAN FRANCISCO, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will report first quarter 2022 financial results on Wednesday, May 4, 2022, after U.S. financial markets close. Management will host a con...
Global Blood Therapeutics is enjoying strong fundamental improvement amid the biotech bear market. Sales of lead drug Oxbryta are ramping up aggressively. With the recent FDA approval to expand Oxbryta's label for children, you can expect more rapid sales growth this year. F...
Baker Brothers’ 13F portfolio value decreased from $22.77B to $20.55B this quarter. Incyte and Legend Biotech stakes were increased this quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~63% of the portfolio. For f...
Gadopiclenol Marketing Authorization dossier submissions accepted for review by EMA and FDA PR Newswire Priority Review granted by US-FDA March 28, 2022 VILLEPINTE, France , March 29, 2022 /PRNewswire/ -- Guerbet (FR0000032526 GBT), a gl...
News, Short Squeeze, Breakout and More Instantly...
Global Blood Therapeutics Inc. Company Name:
GBT Stock Symbol:
NASDAQ Market:
Global Blood Therapeutics Inc. Website:
Guerbet to Spotlight the Novel New Drug Elucirem™ (gadopiclenol) injection at the 2022 Radiological Society of North America Scientific Assembly and Annual Meeting PR Newswire Join us at Booth #1711 Opportunity to learn about the recently US FDA-approved nov...
The healthcare industry is growing at an unprecedented rate, and healthcare stocks are poised to benefit from this growth. This is large because healthcare companies are developing innovative new treatments and technologies that are transforming the way we care for our health. As a resu...
NEW YORK, NY / ACCESSWIRE / September 22, 2022 / New York, New York-Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: EVO Payments...